Intracoastal Capital Amends Kiora Pharma Stake, Kopin & Asher Disclosed

TL;DR

**Intracoastal Capital, Kopin, and Asher updated their Kiora Pharma ownership as of year-end 2023.**

AI Summary

Intracoastal Capital, LLC, along with Mitchell P. Kopin and Daniel B. Asher, filed an amended Schedule 13G/A on February 6, 2024, indicating their beneficial ownership of Kiora Pharmaceuticals Inc. common stock as of December 31, 2023. This amendment, filed under Rule 13d-1(c), updates their previous disclosures regarding their stake in the pharmaceutical company. This matters to investors because it provides transparency into significant ownership positions, which can influence corporate governance and future strategic decisions for Kiora Pharmaceuticals.

Why It Matters

This filing updates the public record on who owns a significant portion of Kiora Pharmaceuticals, which can signal confidence or potential influence over the company's direction.

Risk Assessment

Risk Level: low — This is a routine amendment to a beneficial ownership filing, providing updated information rather than signaling a new, significant event.

Analyst Insight

Investors should note the updated beneficial ownership by Intracoastal Capital, Mitchell P. Kopin, and Daniel B. Asher, and consider if their continued stake aligns with their own investment thesis for Kiora Pharmaceuticals.

Key Players & Entities

• Intracoastal Capital, LLC (company) — filing an amendment to their beneficial ownership statement for Kiora Pharmaceuticals Inc.
• Mitchell P. Kopin (person) — named as a reporting person and group member in the filing
• Daniel B. Asher (person) — named as a group member in the filing
• Kiora Pharmaceuticals Inc. (company) — the subject company whose common stock is being reported
• 03 Life Sciences (company) — an organization name associated with the subject company data

FAQ

Key Financial Figures

• $0.01 — Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class o

Filing Documents

• ea192885-13ga2intra_kiora.htm (SC 13G/A) — 70KB
• 0001213900-24-010336.txt ( ) — 72KB

Ownership

Item 4. Ownership. (a) and (b): As of the close of business on December 31, 2023, each of the Reporting Persons may have been deemed to have beneficial ownership of 117,108 shares of Common Stock, which consisted of (i) 10,858 shares of Common Stock issuable upon exercise of a warrant held by Intracoastal (“ Intracoastal Warrant 1 ”), (ii) 53,125 shares of Common Stock issuable upon exercise of a second warrant held by Intracoastal (“ Intracoastal Warrant 2 ”), (iii) 53,125 shares of Common Stock issuable upon exercise of a third warrant held by Intracoastal (“ Intracoastal Warrant 3 ”), and all such shares of Common Stock in the aggregate represent beneficial ownership of approximately 1.5% of the Common Stock, based on (1) 7,689,240 shares of Common Stock outstanding on November 6, 2023, as reported by the Issuer, plus (2) 10,858 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1, (3) 53,125 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2 and (4) 53,125 shares of Common Stock issuable upon exercise of Intracoastal Warrant 3. (c) Number of shares as to which each Reporting Person has: (i) Sole power to vote or to direct the vote: 0 . (ii) Shared power to vote or to direct the vote: 117,108 . (iii) Sole power to dispose or to direct the disposition of 0 . (iv) Shared power to dispose or to direct the disposition of 117,108 . Item 5. Ownership of Five Percent or Less of a Class If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following þ .

Certification

Item 10. Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11. Page 5 of 6 SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: February 6, 2024 /s/ Mitchell P. Kopin Mitchell P. Kopin /s/ Daniel B. Asher Daniel B. Asher Intracoastal Capital LLC By: /s/ Mitchell P. Kopin Mitchell P. Kopin, Manager Page 6 of 6

View Full Filing

View this SC 13G/A filing on SEC EDGAR